Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.15 - Severity of Lung Cancer Disease in Hospitalized Patients During COVID-19
00:00 - 00:00 | Presenter: Laia Fernández-Mañas
- Abstract
Loading... -
+
P09.28 - Access to Intermediate and Intensive Care for Patients With Lung Cancer During the COVID-19 Period
00:00 - 00:00 | Presenter: Teresa Gorría
- Abstract
Loading...
-
+
P84 - Targeted Therapy - Clinically Focused - ALK
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P84.01 - The ARIA Study: Activity of Next-Generation ALK TKIs Based on ALK Resistance Mutations Detected by Liquid Biopsy in ALK Positive NSCLC Patients.
00:00 - 00:00 | Presenter: Laura Mezquita
- Abstract
Loading...
-
+
MA03 - New and Revisited Prognostic Factors in Early Stage Lung Cancer
- 15:30 - 16:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Early Stage/Localized Disease
-
+
MA03.08 - Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer
15:55 - 16:00 | Presenter: Roxana Reyes
- Abstract
Loading...
-
+
MA08 - Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma
- 16:45 - 17:45
- 1/30/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
MA08.04 - LIPI and Outcomes of Durvalumab as Consolidation Therapy after ChRT in Patients with Locally-Advanced NSCLC
16:50 - 16:55 | Presenter: Mariona Riudavets
- Abstract
Loading...